Lymphoma

Lymphoma is a cancer of the lymphatic system — a malignant proliferation of B cells, T cells, or natural killer cells that have escaped the regulatory mechanisms controlling lymphocyte growth and survival. Unlike carcinomas or sarcomas, which arise from solid tissues, lymphomas are cancers of the immune system itself: the very cells responsible for surveillance and defense become the threat. This paradox — the guardian becoming the invader — makes lymphoma not merely a medical condition but a failure mode of the immune network's own quality control.

The two major categories, Hodgkin lymphoma and non-Hodgkin lymphoma, differ in their cellular origins, clinical behavior, and treatment responses. Hodgkin lymphoma is characterized by the presence of Reed-Sternberg cells — large, abnormal B cells with a distinctive bilateral nucleus — and tends to spread in a predictable, contiguous pattern. Non-Hodgkin lymphoma encompasses a diverse group of B-cell and T-cell malignancies with highly variable aggressiveness, from indolent follicular lymphomas that may not require immediate treatment to aggressive diffuse large B-cell lymphomas that demand urgent chemotherapy.

Lymphoma illustrates the catastrophic consequences of failed network regulation. In normal lymphoid tissue, clonal expansion is tightly coupled to antigen recognition: a B cell proliferates only when it encounters its cognate antigen and receives appropriate T cell help. In lymphoma, this coupling breaks. Genetic mutations — translocations involving MYC, BCL2, or BCL6; mutations in tumor suppressors like TP53 — decouple proliferation from antigen-driven signals. The cell becomes autonomous, replicating without external permission. The immune system often fails to recognize lymphoma cells as foreign because they are derived from self-tissues and may retain self-MHC expression, exploiting the very tolerance mechanisms that prevent autoimmunity.